Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Operating Expenses (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Operating Expenses for 6 consecutive years, with $38.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 25.47% year-over-year to $38.5 million, compared with a TTM value of $144.8 million through Dec 2025, up 10.04%, and an annual FY2025 reading of $144.8 million, up 10.04% over the prior year.
  • Operating Expenses was $38.5 million for Q4 2025 at Cytek Biosciences, up from $36.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $38.5 million in Q4 2025 and bottomed at $13.4 million in Q1 2021.
  • Average Operating Expenses over 5 years is $29.3 million, with a median of $33.2 million recorded in 2023.
  • The sharpest move saw Operating Expenses soared 193.5% in 2021, then fell 8.92% in 2024.
  • Year by year, Operating Expenses stood at $22.3 million in 2021, then skyrocketed by 31.23% to $29.3 million in 2022, then rose by 13.29% to $33.2 million in 2023, then dropped by 7.59% to $30.7 million in 2024, then rose by 25.47% to $38.5 million in 2025.
  • Business Quant data shows Operating Expenses for CTKB at $38.5 million in Q4 2025, $36.7 million in Q3 2025, and $34.5 million in Q2 2025.